103 related articles for article (PubMed ID: 3783206)
1. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.
Rowinsky EK; Ettinger DS; Grochow LB; Brundrett RB; Cates AE; Donehower RC
J Clin Oncol; 1986 Dec; 4(12):1835-44. PubMed ID: 3783206
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
3. Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
Rowinsky EK; Ettinger DS; McGuire WP; Noe DA; Grochow LB; Donehower RC
Cancer Res; 1987 Nov; 47(21):5788-95. PubMed ID: 3664482
[TBL] [Abstract][Full Text] [Related]
4. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Ward FT; Kelley JA; Roth JS; Lombardo FA; Weiss RB; Leyland-Jones B; Chun HG
Cancer Res; 1991 Apr; 51(7):1803-10. PubMed ID: 2004365
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
[TBL] [Abstract][Full Text] [Related]
7. Approaches to optimal dosing of hexamethylene bisacetamide.
Conley BA; Egorin MJ; Sinibaldi V; Sewack G; Kloc C; Roberts L; Zuhowski EG; Forrest A; Van Echo DA
Cancer Chemother Pharmacol; 1992; 31(1):37-45. PubMed ID: 1333894
[TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514
[TBL] [Abstract][Full Text] [Related]
9. The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
Conley BA; Sewack GF; Egorin MJ; Subramanyam B; Page JG; Grieshaber CK
Cancer Chemother Pharmacol; 1991; 28(1):33-8. PubMed ID: 2040031
[TBL] [Abstract][Full Text] [Related]
10. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Rowinsky EK; Donehower RC; Spivak JL; Burke PJ; Griffin CA; Jones RJ
J Natl Cancer Inst; 1990 Dec; 82(24):1926-31. PubMed ID: 2250314
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Rowinsky EK; Conley BA; Jones RJ; Spivak JL; Auerbach M; Donehower RC
Leukemia; 1992 Jun; 6(6):526-34. PubMed ID: 1602791
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
14. Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.
Conley BA; Egorin MJ; Zuhowski EG; Sinibaldi VJ; Peterson DE
Cancer Chemother Pharmacol; 1988; 22(1):65-8. PubMed ID: 3396146
[TBL] [Abstract][Full Text] [Related]
15. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Carducci MA; Gilbert J; Bowling MK; Noe D; Eisenberger MA; Sinibaldi V; Zabelina Y; Chen TL; Grochow LB; Donehower RC
Clin Cancer Res; 2001 Oct; 7(10):3047-55. PubMed ID: 11595694
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
20. Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.
Snyder SW; Egorin MJ; Geelhaar LA; Hamburger AW; Callery PS
Cancer Res; 1988 Jul; 48(13):3613-6. PubMed ID: 3163938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
